Jacques De Grève
Impact in
- Oncology top 0.5%
- PARP inhibition in cancer therapy
- Colorectal Cancer Treatments and Studies
- Hepatology top 0.5%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Oncology 129
- Colorectal Cancer Treatments and Studies 30
- Cancer Treatment and Pharmacology 23
- HER2/EGFR in Cancer Research 20
- PARP inhibition in cancer therapy 16
- Lung Cancer Research Studies 14
- Co-authors
- Erik TeugelsLore DecosterIjeoma Adaku UmeloDenis SchallierBart NeynsArié FigerM. MoscoviciArmando Santoro
- Journals
- Journal of Clinical Oncology (39 papers)Annals of Oncology (15 papers)European Journal of Cancer (9 papers)Journal of Thoracic Oncology (6 papers)Lung Cancer (6 papers)
- Partner nations
- BelgiumUnited StatesNetherlands
In The Last Decade
Jacques De Grève
254 papers receiving 8.0k citations
Hit Papers
Peers
Comparison fields: 5 of 152
- Oncology 3.4k
- Hepatology 996
- Geriatrics and Gerontology 382
- Cancer Research 1.3k
- Reproductive Medicine 485
Countries citing papers authored by Jacques De Grève
This map shows the geographic impact of Jacques De Grève's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacques De Grève with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacques De Grève more than expected).
Fields of papers citing papers by Jacques De Grève
This network shows the impact of papers produced by Jacques De Grève. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacques De Grève. The network helps show where Jacques De Grève may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jacques De Grève, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 0 | |
| 2 | 2023 | 18 | |
| 3 | 2023 | 0 | |
| 4 | 2023 | 3 | |
| 5 | 2021 | 7 | |
| 6 | 2020 | 23 | |
| 7 | PHARMACOKINETICS AND SAFETY OF OLAPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS AND HEPATIC OR RENAL IMPAIRMENT | 2017 | 1 |
| 8 | The Future of Access to Innovative Medicines in Cancer Therapy: Towards Conditional Dialogue Fostering Affordable Therapeutic Innovation | 2016 | 3 |
| 9 | 2015 | 47 | |
| 10 | IMPACT OF GERIATRIC ASSESSMENT ON TREATMENT DECISIONS IN OLDER LUNG CANCER PATIENTS | 2013 | 2 |
| 11 | Performance of two geriatric screening tools in older cancer patients | 2013 | 6 |
| 12 | 2011 | 1 | |
| 13 | First-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicentre academic phase II study in caucasian patients (pts) (NCT00339586) | 2011 | 1 |
| 14 | Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval Hit paper breakdown → | 2010 | 745 |
| 15 | CLINICAL OUTCOME OF PATIENTS TREATED WITH HEPATIC ARTERIAL INFUSION OF OXALIPLATIN AND L-FOLINIC ACID MODULATED 5-FLUOROURACIL FOR INOPERABLE COLORECTAL CANCER LIVER METASTASES, A SINGLE CENTER EXPERIENCE | 2010 | 1 |
| 16 | 2010 | 39 | |
| 17 | 2008 | 15 | |
| 18 | 2007 | 4 | |
| 19 | 2006 | 12 | |
| 20 | A feasibility study on hepatic arterial infusion (HAI) of oxaliplatin followed by I-folinic acid modulated continuous HAI of 5-fluorouracil as second line chemotherapy for stage IV colorectal cancer limited to the liver | 2004 | 2 |
About Jacques De Grève
Jacques De Grève is a scholar working on Oncology, Geriatrics and Gerontology, Pulmonary and Respiratory Medicine, Cancer Research and Genetics, having authored 264 papers that have together received 8.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (41 papers), BRCA gene mutations in cancer (30 papers), Colorectal Cancer Treatments and Studies (30 papers), Cancer Treatment and Pharmacology (23 papers), HER2/EGFR in Cancer Research (20 papers), PARP inhibition in cancer therapy (16 papers), Lung Cancer Research Studies (14 papers) and Hepatocellular Carcinoma Treatment and Prognosis (13 papers). The work is most often cited by research in Oncology (3.4k citations), Hepatology (996 citations), Geriatrics and Gerontology (382 citations), Cancer Research (1.3k citations) and Reproductive Medicine (485 citations). Jacques De Grève has collaborated with scholars based in Belgium, United States and Netherlands. Frequent co-authors include Erik Teugels, Lore Decoster, Ijeoma Adaku Umelo, Denis Schallier, Bart Neyns, Arié Figer, M. Moscovici, Armando Santoro, Chetan Lathia and Christel Fontaine. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Journal of Thoracic Oncology and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.